Nitazoxanide superiority to placebo to treat moderate COVID-19 – A Pilot prove of concept randomized double-blind clinical trial.

BACKGROUND: The absence of specific antivirals to treat COVID-19 leads to the repositioning of candidates’ drugs. Nitazoxanide (NTZ) has a broad antiviral effect. METHODS: This was a randomized, double-blind pilot clinical trial comparing NTZ 600 mg BID versus Placebo for seven days among 50 individ...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:EClinicalMedicine
Main Authors: Blum, Vinicius Fontanesi, Cimerman, Sérgio, Hunter, James R, Tierno, Paulo, Lacerda, Acioly, Soeiro, Alexandre, Cardoso, Florentino, Bellei, Nancy Cristina, Maricato, Juliana, Mantovani, Nathalia, Vassao, Marcella, Dias, Danilo, Galinskas, Juliana, Janini, Luis Mário Ramos, Santos-Oliveira, Joanna Reis, Da-Cruz, Alda Maria, Diaz, Ricardo Sobhie
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2021
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8235996/
https://ncbi.nlm.nih.gov/pubmed/34222847
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eclinm.2021.100981
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados